Uniqure

Yahoo Finance • yesterday

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its... Full story

Yahoo Finance • 5 days ago

uniQure announces pricing of upsized $300M public offering

* uniQure N.V. (NASDAQ:QURE [https://seekingalpha.com/symbol/QURE]) announced on Thursday the pricing of its previously announced underwritten public offering [https://seekingalpha.com/pr/20245492-uniqure-announces-pricing-of-upsized-300... Full story

Yahoo Finance • 5 days ago

uniQure Announces Pricing of Upsized $300 Million Public Offering

LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its... Full story

Yahoo Finance • 6 days ago

Stocks making the biggest moves midday: Mirion Technologies, Freeport-McMoRan, CarMax & more

Check out the companies making the biggest moves midday: Mirion Technologies — The radiation detection name fell more than 8% after it announced a common stock offering of $300 million. Mirion is also selling $250 million in convertible bo... Full story

Yahoo Finance • 6 days ago

Uniqure (QURE) Soars 275% on Stellar Clinical Trial for Huntington’s Disease

We recently published 10 Stocks Crushing Wall Street, AI Stocks Dominate. Uniqure NV (NASDAQ:QURE) is one of the top performers on Tuesday. Shares of Uniqure NV soared by as much as 275 percent on Wednesday to hit a new all-time high as i... Full story

Yahoo Finance • 6 days ago

Stocks making the biggest premarket moves: Intel, Oracle, Lithium Americas, Opendoor and more

Check out the companies making the biggest moves in premarket trading: Oracle — The database software company fell 3% as worries around the AI trade continue to drag the stock lower. Rothschild & Co Redburn initiated coverage of Oracle wit... Full story

Yahoo Finance • 6 days ago

uniQure Announces $200 Million Proposed Public Offering

LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenc... Full story

Yahoo Finance • 7 days ago

uniQure succeeds in pivotal trial for one-time Huntington’s disease therapy

Hailshadow uniQure (NASDAQ:QURE [https://seekingalpha.com/symbol/QURE]) announced on Wednesday that its one-time gene therapy AMT-130 reached the main goals in a pivotal Phase 2/3 trial for patients with Huntington’s disease, a rare neuro... Full story

Yahoo Finance • 7 days ago

uniQure announces refinancing of $50M debt and secures additional $125M in non-dilutive funding

* uniQure (NASDAQ:QURE [https://seekingalpha.com/symbol/QURE]) said on Wednesday that it entered into a $175M non-dilutive senior secured term loan facility [https://seekingalpha.com/pr/20242480-uniqure-announces-refinancing-of-existing-... Full story

Yahoo Finance • 7 days ago

uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding

~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~ ~ Additional $100 million available subject to regulatory and financial milestones ~ ~ Additional $25 million available subject to Hercules’ appr... Full story

Yahoo Finance • 7 days ago

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease

~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external control ~ ~ High-dose AMT-130 also demon... Full story

Yahoo Finance • 26 days ago

uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~ ~ All patients in first cohort discontinued enzyme replacement therapy ~ ~ Preliminary data show AMT-191 ha... Full story

Yahoo Finance • 2 months ago

UniQure outlines planned BLA submission for AMT-130 in Q1 2026 amid regulatory alignment and pipeline momentum

Earnings Call Insights: uniQure N.V. (QURE) Q2 2025 MANAGEMENT VIEW * CEO Matthew Kapusta highlighted that "the first half of 2025 has been tremendously productive for the company as we advance AMT-130 towards potentially becoming the... Full story

Yahoo Finance • 2 months ago

uniQure NV (NASDAQ:QURE) Posts Q2 2025 Earnings: EPS Beat Offsets Revenue Miss as Regulatory Progress Boosts Shares

UNIQURE NV (NASDAQ:QURE [https://www.chartmill.com/stock/quote/QURE]) REPORTS Q2 2025 EARNINGS: MIXED RESULTS AMID REGULATORY PROGRESS uniQure NV released its second-quarter 2025 financial results, revealing a mixed performance relative t... Full story

Yahoo Finance • 2 months ago

uniQure gives mixed Q2 results

* uniQure press release [https://seekingalpha.com/pr/20180491-uniqure-announces-second-quarter-2025-financial-results-and-highlights-of-recent-company] (NASDAQ:QURE [https://seekingalpha.com/symbol/QURE]): Q2 GAAP EPS of -$0.69 beats by... Full story

Yahoo Finance • 2 months ago

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 topline three-year data in September 20... Full story

Yahoo Finance • 2 months ago

uniQure Q2 2025 Earnings Preview

* uniQure (NASDAQ:QURE [https://seekingalpha.com/symbol/QURE]) is scheduled to announce Q2 earnings results on Tuesday, July 29th, before market open. * The consensus EPS Estimate is -$0.88 [https://seekingalpha.com/symbol/QURE/earning... Full story

Yahoo Finance • 2 months ago

uniQure to Announce Second Quarter 2025 Financial Results

LEXINGTON, Mass. and AMSTERDAM, July 22, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2025 finan... Full story

Yahoo Finance • 3 months ago

uniQure N.V. chief legal officer Potts sells $70k in shares

uniQure N.V. (NASDAQ:QURE) Chief Legal Officer Jeannette Potts sold 4,670 ordinary shares of the company on June 16, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average... Full story

Yahoo Finance • 4 months ago

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer

~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transforma... Full story